STAT+: Pharmalittle: We’re reading about a Trump drug pricing flaw, a Gilead deal, and more

President Donald Trump’s most-favored-nation drug pricing push appears to have a problem baked into its design: by the administration’s own telling, the deals are structured less to force down U.S. prices quickly than to stop drugmakers from charging less in other wealthy countries. That is a very different promise from the broad political sales pitch. And if companies can simply wait out the contracts before launching new drugs abroad, the whole thing starts to look like a pricing cudgel with a clock attached, not a durable way to make medicines cheaper for Americans.

That gap is visible in comments from Chris Klomp, the Medicare director at the U.S. Department of Health and Human Services. In STAT News, John Wilkerson reported that Klomp described the policy as a way to prevent companies from undercutting the United States in peer countries. Klomp made the same narrowing move in earlier remarks covered by STAT News, where Tara Bannow reported that TrumpRx itself was meant for cash-pay patients, not for most Americans with insurance. For a White House slogan pitched as a broad assault on high drug prices, that is a notably smaller target.

The bigger structural flaw is timing. Wilkerson reported that Rachel Sachs, a professor of law at Washington University in St. Louis, sees a loophole in the policy’s design: if a company expects an MFN agreement to run only a few years, it can delay launching a new drug in Europe or another wealthy market until the agreement expires. No foreign launch means no lower foreign benchmark to import back into the United States. The administration can talk tough; the product can simply arrive later.

That is not just a theoretical lawyer’s puzzle. STAT News previously reported that at least some of these agreements run for three years, which matters because Trump would leave office before many of those clocks run out. The most accessible primary evidence sits in a Dec. 2025 Form 6-K filed with the U.S. Securities and Exchange Commission by GSK, the British drugmaker, which said its arrangement provides clarity on the future U.S. pricing framework and exempts GSK and ViiV Healthcare, the HIV drug company majority-owned by GSK, from Section 232 tariffs for three years. That is long enough to make delay a rational strategy.

Once you view the policy through that lens, the incentives get awkward fast. If drugmakers want to preserve U.S. pricing flexibility, they can seek higher launch prices overseas, launch first only in markets that will tolerate those prices, or hold back products in countries that will not. STAT News, in reporting by Andrew Joseph, described pressure in Europe around higher prices, launch sequencing, and threats to withhold some products. That does not prove companies are already executing Sachs’ loophole exactly as described. It does show the incentives behind her warning are already visible. The administration’s campaign language is about cheaper drugs for Americans; the mechanism starts to look more like pricier or later drugs for everyone else.

Even the domestic effect is narrower than the branding suggests. Reuters, in a report by Mariam Sunny and Michael Erman, said the administration is still working with drugmakers on legislative text to codify the policy, a reminder that the framework remains unsettled. And NPR reported in January that all 16 participating companies still raised list prices on some products this year, while the agreements mostly touched Medicaid, future launches, and cash-pay channels rather than the core insured market. In other words: the plan has been sold as a wide consumer benefit, but its current footprint looks selective, partial, and very dependent on what has not launched yet.

Outside fact-checkers have been blunt about that mismatch. FactCheck.org found no evidence that the deals had produced broad price declines for Americans overall and noted that key implementation details remain murky. That does not mean the policy has no leverage. It does mean the rhetoric has outrun the mechanism.

There is a dry little irony here. A policy meant to import lower prices from abroad may work best by discouraging low foreign prices from existing in the first place. If Klomp is right that the goal is to stop companies from offering better terms in other wealthy countries, then the administration is not really building a machine that discovers the cheapest price. It is trying to stop anyone else from getting one first.

What to watch next is whether Congress actually codifies the MFN framework, whether more SEC filings reveal similar three-year terms, and whether companies begin quietly spacing out launches in Europe and other peer markets. If that happens, the Trump administration will still be able to say it fought drugmakers. Patients, meanwhile, may be left with the sort of victory that looks terrific in a press release and much less impressive at the pharmacy counter.